Numerous studies have described how genetic loss-of-function of SARM1 can contribute to the protection of axons and prevent the occurrence of PN in preclinical CIPN models of VCR, PTX (paclitaxel, PAC in the above part), or bortezomib administration [13,26,27]. Here, SARM1 is linked to poikiloderma with neutropenia.